ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
A Dose-Finding and Double Blinded Study of JNS020 QD(Fentanyl) in Patients With Cancerous Pain Previously Untreated With Opioid Analgesics

This study is currently recruiting participants.
Verified by Janssen Pharmaceutical K.K., August 2008

Sponsored by: Janssen Pharmaceutical K.K.
Information provided by: Janssen Pharmaceutical K.K.
ClinicalTrials.gov Identifier: NCT00644787
  Purpose

The purpose of this study is to evaluate the effectiveness and safety of JNS020 QD(fentanyl) at an initial dose of 12.5 mcg/h in cancer pain patients who require the use of opioid analgesics because of inadequate response to non-opioid analgesics (e.g., non-steroidal anti-inflammatory drugs) and to assess the noninferiority of JNS020 QD(fentanyl) to JNS005 in effectiveness in patients whose pain is controlled with JNS020 QD(fentanyl).


Condition Intervention Phase
Cancer
Pain
Drug: fentanyl
Phase II
Phase III

MedlinePlus related topics:   Cancer   

ChemIDplus related topics:   Fentanyl Citrate    Fentanyl   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Double-Blind, Parallel Assignment, Safety/Efficacy Study
Official Title:   A Phase 2/3 Dose-Finding and Double Blinded Study of JNS020 QD(Fentanyl) in Comparison With JNS005 in Patients With Cancerous Pains Previously Untreated With Opipoid Analgesics

Further study details as provided by Janssen Pharmaceutical K.K.:

Primary Outcome Measures:
  • Period 1: Dose titration success rate Period 2: The mean VAS score for the last 3 days before the completion (or discontinuation) of Period 2

Secondary Outcome Measures:
  • Patient's global assessment, pain intensity (VAS), pain control achievement rate, pain intensity (categorical scale), total duration of pain per day, rescue dose, physician's global assessment

Estimated Enrollment:   154
Study Start Date:   December 2007

Detailed Description:

Fentanyl patch system for 3-day application is widely used for management of cancer related pain. Patch for 1-day application is useful and it can allow daily dose adjustment, an optimal clinical dose can be selected for patients previously untreated with opioid analgesics. This is a multicenter study to evaluate the effectiveness and safety of JNS020 QD(fentanyl), consisting of two periods. Period 1 is non-blind, uncontrolled, Period 2 is double-blinded, positive control, randomized. JNS005, a fentanyl patch for 3-day application, is used as control drug. Patients receive initially 12.5 mcg/h JNS020 QD(fentanyl), subsequently the dose of JNS020 QD(fentanyl) can be increased up to 100 mcg/h in Period 1. Patients are randomly allocated to either the JNS020 QD(fentanyl) group or the JNS005 group in Period 2. Patients receive JNS020 QD(fentanyl) at the same dose as used at period 1 in the JNS020 QD(fentanyl) group. Patients receive JNS005 at the same daily dose as used at period 1 in the JNS005 group. The duration of period 2 is 10 days. The VAS score changes of each group in period 2 are compared to assess the noninferiority of JNS020 QD(fentanyl) to JNS005.

Patients receive initially 12.5 mcg/h JNS020 QD(fentanyl), subsequently the dose of JNS020 QD(fentanyl) can be increased up to 100 mcg/h in Period 1. The duration of Period 1 is 5 to 14 days. In Period 2, the assigned patch is applied for 10 days at the same dose as used at the end of Period 1.

  Eligibility
Ages Eligible for Study:   20 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  • Cancer pain patients previously untreated with opioid analgesics for the pain
  • Patients treated with non-opioid analgesics (e.g., non-steroidal anti-inflammatory drugs)
  • Patients with a pain score of >= 35 mm on a 100-mm visual analog scale (VAS)
  • Patients who are considered to have "insufficient response" to non-opioid analgesics and to require the treatment with opioid analgesics by the physician
  • Patients who have an established diagnosis of cancer and are notified of the disease

Exclusion Criteria:

  • Patients with impaired respiratory function due to chronic lung disease or others
  • Patients with asthma
  • Patients with bradyarrhythmia
  • Patients who are found to have any of the following measurements indicative of hepatic or renal impairment with laboratory tests during the pre-treatment observation period: AST (GOT) > 5 times the upper limit of reference range, ALT (GPT) > 5 times the upper limit of reference range, serum creatinine > 3 times the upper limit of reference range
  • Patients with any organic cerebral damage, such as brain tumor, accompanied by increased intracranial pressure, disturbance of consciousness, coma, or respiratory disturbance
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00644787

Contacts
Contact: Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions:     info1@veritasmedicine.com    

Show 52 study locations  Show 52 Study Locations

Sponsors and Collaborators
Janssen Pharmaceutical K.K.

Investigators
Study Director:     Janssen Pharmaceutical K.K. Clinical Trial     Janssen Pharmaceutical K.K.    
  More Information

To learn how to participate in this trial please click here.  This link exits the ClinicalTrials.gov site
 

Study ID Numbers:   CR014899
First Received:   March 24, 2008
Last Updated:   August 29, 2008
ClinicalTrials.gov Identifier:   NCT00644787
Health Authority:   Japan: Japan Pharmaceuticals And Medical Devices Evaluation Center

Keywords provided by Janssen Pharmaceutical K.K.:
pain  
non opioid analgesics  
control  
patch  
cancer  

Study placed in the following topic categories:
Signs and Symptoms
Fentanyl
Pain

Additional relevant MeSH terms:
Anesthetics, Intravenous
Physiological Effects of Drugs
Central Nervous System Depressants
Anesthetics
Narcotics
Pharmacologic Actions
Adjuvants, Anesthesia
Sensory System Agents
Anesthetics, General
Therapeutic Uses
Analgesics
Peripheral Nervous System Agents
Central Nervous System Agents
Analgesics, Opioid

ClinicalTrials.gov processed this record on September 05, 2008




Links to all studies - primarily for crawlers